This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Yu AP, Johnson S, Wang S-T, Atanasov P, Tang J, Wu E, Chao J, Mulani PM.Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. PharmacoEconomics 27: 609-621, No. 7, Jul 2009
Rights and permissions
About this article
Cite this article
Adalimumab strides forward in Crohn's disease. Pharmacoecon. Outcomes News 587, 5 (2009). https://doi.org/10.2165/00151234-200905870-00012
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905870-00012